DE69900841D1 - Durch enzymkatalyse erhaltene therapeutische substanzen. - Google Patents

Durch enzymkatalyse erhaltene therapeutische substanzen.

Info

Publication number
DE69900841D1
DE69900841D1 DE69900841T DE69900841T DE69900841D1 DE 69900841 D1 DE69900841 D1 DE 69900841D1 DE 69900841 T DE69900841 T DE 69900841T DE 69900841 T DE69900841 T DE 69900841T DE 69900841 D1 DE69900841 D1 DE 69900841D1
Authority
DE
Germany
Prior art keywords
cell
prodrug
endogenous
selective substrate
enzym
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69900841T
Other languages
English (en)
Other versions
DE69900841T2 (de
Inventor
Michael Shepard
P Groziak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celmed Oncology USA Inc
Original Assignee
Celmed Oncology USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celmed Oncology USA Inc filed Critical Celmed Oncology USA Inc
Publication of DE69900841D1 publication Critical patent/DE69900841D1/de
Application granted granted Critical
Publication of DE69900841T2 publication Critical patent/DE69900841T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A61K47/556—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells enzyme catalyzed therapeutic agent [ECTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/67—Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
DE69900841T 1998-01-23 1999-01-22 Durch enzymkatalyse erhaltene therapeutische substanzen. Expired - Lifetime DE69900841T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US7226498P 1998-01-23 1998-01-23
US7695098P 1998-03-05 1998-03-05
US10863498P 1998-11-16 1998-11-16
PCT/US1999/001332 WO1999037753A1 (en) 1998-01-23 1999-01-22 Enzyme catalyzed therapeutic agents

Publications (2)

Publication Number Publication Date
DE69900841D1 true DE69900841D1 (de) 2002-03-14
DE69900841T2 DE69900841T2 (de) 2002-10-02

Family

ID=27372051

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69900841T Expired - Lifetime DE69900841T2 (de) 1998-01-23 1999-01-22 Durch enzymkatalyse erhaltene therapeutische substanzen.

Country Status (16)

Country Link
US (3) US6339151B1 (de)
EP (2) EP1167972B1 (de)
JP (2) JP2002500880A (de)
CN (1) CN1192102C (de)
AT (1) ATE212661T1 (de)
AU (1) AU753155B2 (de)
BR (1) BR9907736A (de)
CA (1) CA2317505C (de)
DE (1) DE69900841T2 (de)
DK (1) DK1045897T3 (de)
ES (1) ES2172303T3 (de)
HK (2) HK1039520A1 (de)
IL (1) IL137164A0 (de)
PT (1) PT1045897E (de)
TW (1) TWI244924B (de)
WO (1) WO1999037753A1 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2180730T3 (es) 1995-02-01 2003-02-16 Resprotect Gmbh Uso de nucleosidos sustituidos en 5 para inhibir la formacion de resistencias en el tratamiento con citostaticos.
JP2001512830A (ja) * 1997-08-08 2001-08-28 ニューバイオティックス インコーポレイテッド 生物療法耐性および化学療法耐性を克服するための方法および組成物
US6703374B1 (en) 1997-10-30 2004-03-09 The United States Of America As Represented By The Department Of Health And Human Services Nucleosides for imaging and treatment applications
US7462605B2 (en) * 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
US6339151B1 (en) * 1998-01-23 2002-01-15 Newbiotics, Inc. Enzyme catalyzed therapeutic agents
CA2379988C (en) * 1999-07-22 2010-10-19 Newbiotics, Inc. Enzyme catalyzed therapeutic activation
EP1200130A2 (de) * 1999-07-22 2002-05-02 Newbiotics, Inc. Vefahren zur behandlung von therapie-resistente tumoren
US6683061B1 (en) * 1999-07-22 2004-01-27 Newbiotics, Inc. Enzyme catalyzed therapeutic activation
MXPA02000761A (es) * 1999-07-22 2002-08-12 Newbiotics Inc Agentes terapeuticos anti-infecciosos catalizados por enzima.
US6673564B2 (en) * 1999-10-18 2004-01-06 Millennium Pharmaceuticals, Inc. Methods for using 22045, a human cyclic nucleotide phosphodiesterase
US20030212037A1 (en) * 2000-12-21 2003-11-13 Christopher Boyer Use of bvdu for inhibiting the growth of hyperproliferative cells
AU2451601A (en) * 1999-12-23 2001-07-03 Newbiotics, Inc. Use of bvdu for inhibiting the growth of hyperproliferative cells
US20030130179A1 (en) * 2000-07-20 2003-07-10 Shepard H. Michael Methods for identifying therapeutic targets for treating infectious disease
AU2001277093A1 (en) * 2000-07-20 2002-02-05 Newbiotics, Inc. Methods for identifying therapeutic targets
KR100749160B1 (ko) * 2000-07-21 2007-08-14 길리애드 사이언시즈, 인코포레이티드 포스포네이트 뉴클레오티드 유사체의 전구 약물의 제조방법
AU2002241911B9 (en) * 2001-01-19 2007-01-25 Celmed Oncology (Usa), Inc. Methods to treat autoimmune and inflammatory conditions
DE10108851A1 (de) * 2001-02-23 2002-09-12 Resprotect Gmbh Verwendung von 5'-substituierten Nukleosiden und/oder deren Prodrugs zur resistenzfreien Therapie von Infektionskrankheiten
CA2447470A1 (en) * 2001-05-09 2002-11-14 Newbiotics, Inc. Peptide deformylase activated prodrugs
US20030212147A1 (en) * 2001-07-12 2003-11-13 Chung Sum Man Stephen Enzyme activated chemotherapy of liver cancer
BR0211900A (pt) * 2001-08-14 2004-08-24 Toyama Chemical Co Ltd Método para inibição do desenvolvimento de vìrus e/ou virucida, análogos de nucleotìdeo de pirazina e de nucleosìdeo de pirazina, precursor do inibidor da polimerase de rna, inibidor da polimerase de rna, método para tratar pacientes infectados por vìrus, e, usos de um análogo de nucleotìdeo de pirazina ou um sal deste e de um análogo de nucleosìdeo de pirazina ou um sal deste
MXPA04004882A (es) * 2001-11-23 2005-04-11 Chugai Pharmaceutical Co Ltd Metodo para la identificacion de enzimas que tienen como objetivo tumores.
US20030152747A1 (en) * 2002-01-11 2003-08-14 The Garland Company, Inc., An Ohio Corporation Roofing materials
EP1499318A4 (de) * 2002-04-18 2006-07-19 Celmed Oncology Usa Inc Peptiddeformylase-aktivierte prodrugs
TW200418508A (en) 2002-11-14 2004-10-01 Newbiotics Inc Peptide deformylase activated prodrugs
EP1599484A2 (de) * 2003-02-21 2005-11-30 Chugai Seiyaku Kabushiki Kaisha Verfahren zur herstellung von hexacyclischen camptothecin derivaten
WO2004111192A2 (en) * 2003-05-29 2004-12-23 The Scripps Research Institute Targeted delivery to legumain-expressing cells
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
AU2004274021B2 (en) * 2003-09-18 2009-08-13 Isis Pharmaceuticals, Inc. 4'-thionucleosides and oligomeric compounds
GB0401088D0 (en) 2004-01-19 2004-02-18 Univ Cardiff Phosphoramidate derivatives
CA2563502A1 (en) * 2004-04-09 2005-10-20 Chugai Seiyaku Kabushiki Kaisha Novel water-soluble prodrug
US7309589B2 (en) 2004-08-20 2007-12-18 Vironix Llc Sensitive detection of bacteria by improved nested polymerase chain reaction targeting the 16S ribosomal RNA gene and identification of bacterial species by amplicon sequencing
GB0505781D0 (en) * 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
WO2006110531A2 (en) * 2005-04-07 2006-10-19 Health Research Inc. Acyl homoserine lactones for inhibition of cell growth
WO2006121820A1 (en) * 2005-05-05 2006-11-16 Valeant Research & Development Phosphoramidate prodrugs for treatment of viral infection
TW200744603A (en) * 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
CA2626330A1 (en) * 2005-10-19 2007-04-26 Chugai Seiyaku Kabushiki Kaisha Preventive or therapeutic agents for pancreatic cancer, ovarian cancer, or liver cancer comprising a novel water-solube prodrug
WO2007064759A2 (en) * 2005-11-29 2007-06-07 The Scripps Research Institute Inhibiting tumour cell invasion, metastasis and angiogenesis through targetting legumain
DE102006037786A1 (de) 2006-08-11 2008-03-20 Resprotect Gmbh Nukleoside, diese enthaltendes Arzneimittel und deren Verwendung
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
EA019295B1 (ru) * 2008-12-23 2014-02-28 Джилид Фармассет, Ллс. Соединения пуриновых нуклеозидов и способ их получения
TWI576352B (zh) * 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
WO2011005525A2 (en) 2009-06-22 2011-01-13 Health Research Inc. Prodrug anti-cancer therapy
AU2011235044A1 (en) 2010-03-31 2012-11-22 Gilead Pharmasset Llc Stereoselective synthesis of phosphorus containing actives
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
JP6163105B2 (ja) * 2010-11-16 2017-07-12 ユニバーシティー オブ サザン カリフォルニア 体性幹細胞の非対称分裂を促進するためのｃｂｐ／カテニン拮抗剤
WO2012075140A1 (en) 2010-11-30 2012-06-07 Pharmasset, Inc. Compounds
KR101969333B1 (ko) * 2011-02-18 2019-04-16 더 유에이비 리서치 파운데이션 푸린 뉴클레오시드 포스포릴라아제 또는 뉴클레오시드 하이드롤라아제 프로드러그의 증강된 치료적 용도
BR112013021986B1 (pt) * 2011-03-01 2021-07-27 Nucana Biomed Limited Derivados de fosforamidato de 5-fluoro-2'-desoxiuridina, seus usos e seu processo de preparação, composição farmacêutica e seu método de preparação
CA2840242C (en) 2011-09-16 2019-03-26 Gilead Sciences, Inc. Methods for treating hcv
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
HUE044605T2 (hu) 2012-11-16 2019-11-28 Univ College Cardiff Consultants Ltd RP/SP gemcitabin-[fenil-(benziloxi-L-alaninil)]-foszfát keveréke
CN105748499B (zh) 2013-01-31 2018-12-28 吉利德制药有限责任公司 两个抗病毒化合物的联用制剂
BR112015025716A2 (pt) 2013-04-12 2017-07-18 Achillion Pharmaceuticals Inc pró-fármacos de nucleosídeo submetidos a deutério úteis para o tratamento de hcv
MX2016002185A (es) 2013-08-27 2016-06-06 Gilead Pharmasset Llc Formulacion combinada de dos compuestos antivirales.
US9828409B2 (en) * 2014-03-19 2017-11-28 Minghong Zhong Bridged-cyclo-ProTides as prodrugs of therapeutic nucleosides and nucleotides
HUE036011T2 (hu) 2014-06-25 2018-06-28 NuCana plc Készítmény, mely tartalmaz egy gemcitabin-pro-gyógyszert
SG11201608808TA (en) 2014-06-25 2016-11-29 Nucana Biomed Ltd Gemcitabine prodrugs
US10071112B2 (en) 2014-10-08 2018-09-11 Epigenetics Pharma Llc Vitamin E-nucleoside prodrugs
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
CN109207551B (zh) * 2017-07-07 2023-05-26 上海睿智化学研究有限公司 一种筛选叶酸代谢相关药物的方法

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB982776A (en) * 1962-01-24 1965-02-10 Wellcome Found 2-deoxyuridines and their use in pharmaceutical compositions having anti-immune activity
JPS5017989B1 (de) * 1970-12-24 1975-06-25
US4267171A (en) 1979-07-02 1981-05-12 The Regents Of The University Of California C-5 Substituted cytosine nucleosides
US4247544A (en) 1979-07-02 1981-01-27 The Regents Of The University Of California C-5 Substituted uracil nucleosides
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
JPS5843993A (ja) 1981-09-09 1983-03-14 Yamasa Shoyu Co Ltd １−β−Ｄ−アラビノフラノシル−（Ｅ）−５−（２−ハロゲノビニル）ウラシル−５′−りん酸およびその製造法
EP0095294A1 (de) 1982-05-22 1983-11-30 Beecham Group Plc Deoxyuridin-Derivate, ihre Herstellungsverfahren und ihre medizinische Anwendung
DE3229169A1 (de) 1982-08-05 1984-02-09 Robugen GmbH Pharmazeutische Fabrik, 7300 Esslingen Verwendung von 5-alkylpyrimidinnukleosiden und deren derivate als zytostatika
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4948882A (en) 1983-02-22 1990-08-14 Syngene, Inc. Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
RO88451A2 (ro) 1984-06-05 1986-01-30 Intreprinderea De Antibiotice,Ro Derivati ai acidului 7-aminocefalosporanic si procedeu de preparare aacestora
US5077282A (en) 1986-10-23 1991-12-31 American Cyanamid Company Solubilized pro-drugs
US5212291A (en) 1986-10-23 1993-05-18 American Cyanamid Company Anthracycline derivatives as solubilized pro-drugs
US5116827A (en) 1986-10-23 1992-05-26 American Cyanamid Company Quinolinecarboxylic acid derivatives as solubilized pro-drugs
US5077283A (en) 1986-10-23 1991-12-31 American Cyanamid Company Solubilized imidazole pro-drugs
US5070082A (en) * 1986-10-23 1991-12-03 American Cyanamid Company Solubilized pro-drugs
US5116822A (en) 1986-10-24 1992-05-26 Stichting Rega Vzw Therapeutic application of dideoxycytidinene
US4963533A (en) 1986-10-24 1990-10-16 Stichting Rega Vzw (Rega) Therapeutic application of dideoxycytidinene
NL8700366A (nl) 1987-02-13 1988-09-01 Stichting Rega V Z W Combinatie van fu met bvdu als middel tegen adenocarcinoom.
US5085983A (en) 1988-08-19 1992-02-04 City Of Hope Detection of human tumor progression and drug resistance
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
EP0311107A3 (de) 1987-10-08 1990-04-18 Stichting REGA V.Z.W. Anti-HIV-aktive 3'-Fluoro-purin-2',3'-dideoxyriboside
JPH01301690A (ja) 1987-10-08 1989-12-05 Stichting Rega Vzw 抗ｈｉｖ活性をもつ３’−アジド−２，６−ジアミノプリン−２’，３’−ジデオキシリボシド
US4963263A (en) 1988-03-24 1990-10-16 Terrapin Technologies, Inc. Method of identity analyte-binding peptides
US5300425A (en) 1987-10-13 1994-04-05 Terrapin Technologies, Inc. Method to produce immunodiagnostic reagents
US5217869A (en) 1987-10-13 1993-06-08 Terrapin Technologies, Inc. Method to produce immunodiagnostic reagents
US5133866A (en) 1988-03-24 1992-07-28 Terrapin Technologies, Inc. Method to identify analyte-bending ligands
US5338659A (en) 1991-04-02 1994-08-16 Terrapin Technologies, Inc. Method for determining analyte concentration by cross-reactivity profiling
EP0316592A3 (de) 1987-11-13 1990-09-19 Stichting REGA V.Z.W. 3'-Fluor-2',3'-dideoxyuridin und seine therapeutische Verwendung
CA1317291C (en) 1987-12-14 1993-05-04 Naeem Botros Hanna Antitumor 6-sulfenamide, 6-sulfinamide and 6-sulfonamide purines, purine nucleosides, purine nucleotides and related compounds
JPH03504492A (ja) * 1988-02-24 1991-10-03 エンスティテュ　デ　ルシェルシェ　シミク　エ　ビョーロジク　アプリケ　（イ　エール　セ　エ　ベ　ア） α‐アミノアシル基により５‐、３’‐、又は５’‐の位置で置換された２’‐デオキシウリジンの新しい誘導体及びその生成方法及びそれらの存在する薬剤
WO1990003978A1 (en) 1988-10-03 1990-04-19 Stichting Rega Vzw 5-halogeno-3'-fluoro-2',3'-dideoxyuridine compounds and their therapeutic application
US5596018A (en) 1988-12-28 1997-01-21 Toray Industries, Inc. Antiviral agents against aids-causing virus
US5433955A (en) 1989-01-23 1995-07-18 Akzo N.V. Site specific in vivo activation of therapeutic drugs
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
SK280313B6 (sk) 1990-04-24 1999-11-08 �Stav Organick� Chemie A Biochemie Av �R N-(3-fluór-2-fosfonylmetoxypropyl)deriváty purínov
AU7979491A (en) 1990-05-03 1991-11-27 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
GB9010242D0 (en) 1990-05-08 1990-06-27 British Telecomm Optical signal regenerator and optical communications system incorporating same
US5137724A (en) 1990-05-23 1992-08-11 Stichting Rega Vzw Combinations of TS-inhibitors and viral TK-inhibitors in antiherpetic medicines
US5627165A (en) 1990-06-13 1997-05-06 Drug Innovation & Design, Inc. Phosphorous prodrugs and therapeutic delivery systems using same
US5608046A (en) 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
EP0630412B1 (de) 1991-04-29 1998-11-11 Terrapin Technologies, Inc. Verfahren zur erkennung und behandlung anomaler zellen
US5556942A (en) * 1991-04-29 1996-09-17 Terrapin Technologies, Inc. Glutathione S-transferase-activated compounds
US5645988A (en) 1991-05-08 1997-07-08 The United States Of America As Represented By The Department Of Health And Human Services Methods of identifying drugs with selective effects against cancer cells
EP0513917B2 (de) 1991-05-16 2001-03-07 Glaxo Group Limited Nukleosidanalogen enthaltende Antiviren-Zubereitungen
ATE138928T1 (de) 1991-09-04 1996-06-15 Stichting Rega V Z W Substituierte nukleosidderivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen
US5233031A (en) 1991-09-23 1993-08-03 University Of Rochester Phosphoramidate analogs of 2'-deoxyuridine
US5879700A (en) 1991-10-15 1999-03-09 Hostetler; Karl Y. Nucleoside analogue phosphates for topical use
US5274162A (en) * 1991-12-13 1993-12-28 Arnold Glazier Antineoplastic drugs with bipolar toxification/detoxification functionalities
WO1993013740A2 (en) 1991-12-31 1993-07-22 Worcester Foundation For Experimental Biology Antiparasitic oligonucleotides active against drug resistant malaria
US5430148A (en) 1992-03-31 1995-07-04 Agouron Pharmaceuticals, Inc. Antiproliferative quinazolines
US5668828A (en) * 1992-05-08 1997-09-16 Sanconix, Inc. Enhanced frequency agile radio
US6057305A (en) 1992-08-05 2000-05-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiretroviral enantiomeric nucleotide analogs
US5516631A (en) 1992-10-13 1996-05-14 La Jolla Cancer Research Foundation Method of inhibiting replication of hyperproliferative cells
IL105244A (en) * 1993-03-31 2003-07-31 Dpharm Ltd Prodrugs with enhanced penetration into cells
US5502037A (en) * 1993-07-09 1996-03-26 Neuromed Technologies, Inc. Pro-cytotoxic drug conjugates for anticancer therapy
US5798340A (en) 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
EP0720615B1 (de) * 1993-09-21 2000-07-26 Amersham Pharmacia Biotech UK Limited Elongation, amplifikation und sequenzierung unter verwendung eines chimären oligonucleotids
US5908919A (en) 1993-10-01 1999-06-01 Terrapin Technologies Urethane mediated, GST specific molecular release systems
GB9323008D0 (en) 1993-11-05 1994-01-05 Connors Thomas Improvements relating to cancer therapy
US5457187A (en) * 1993-12-08 1995-10-10 Board Of Regents University Of Nebraska Oligonucleotides containing 5-fluorouracil
US5521161A (en) 1993-12-20 1996-05-28 Compagnie De Developpment Aguettant S.A. Method of treating HIV in humans by administration of ddI and hydroxycarbamide
GB9415167D0 (en) * 1994-07-27 1994-09-14 Springer Caroline J Improvements relating to cancer therapy
US5556992A (en) * 1994-09-02 1996-09-17 Universite De Montreal Novel rhodamine derivatives for photodynamic therapy of cancer and in vitro purging of the leukemias
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5968910A (en) 1994-11-30 1999-10-19 Jan M. R. Balzarini Compositions containing two or three inhibitors of different HIV reverse transcriptases
ES2180730T3 (es) 1995-02-01 2003-02-16 Resprotect Gmbh Uso de nucleosidos sustituidos en 5 para inhibir la formacion de resistencias en el tratamiento con citostaticos.
US5705336A (en) * 1995-03-07 1998-01-06 The United States Of America As Represented By The Department Of Health And Human Services Assay for sensitivity of tumors to DNA-platinating chemotherapy
GB9505025D0 (en) 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
IL117940A (en) 1995-04-19 2003-06-24 Kumiai Chemical Industry Co Benzylsulfide derivatives, process for their production and insecticide compositions containing them
US5856464A (en) 1995-06-07 1999-01-05 Lajolla Pharmaceutical Company Selective capping solution phase oligonucleotide synthesis
US5998151A (en) * 1995-12-01 1999-12-07 The United States Of America As Represented By The Department Of Health And Human Services Methods for predicting the efficacy of a chemotherapeutic regimen for gastrointestinal cancers using antibodies specific for thymidylate synthase
US5981507A (en) 1995-12-14 1999-11-09 Advanced Magnetics, Inc. Polymeric carriers linked to nucleotide analogues via a phosphoramide bond
US5880097A (en) 1996-01-04 1999-03-09 Terrapin Techologies, Inc. Tethered prodrugs
JP2000504670A (ja) * 1996-01-31 2000-04-18 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 腫瘍細胞の成長を抑制する方法
RU2111970C1 (ru) 1996-06-25 1998-05-27 Иван Игоревич Федоров 3'-оксимино-2',3'-дидезоксинуклеозиды
GB9708611D0 (en) 1997-04-28 1997-06-18 Univ Cardiff Chemical compounds
WO1999006072A1 (en) 1997-07-30 1999-02-11 Boehringer Mannheim Corporation Cyclized prodrugs
JP2001512830A (ja) * 1997-08-08 2001-08-28 ニューバイオティックス インコーポレイテッド 生物療法耐性および化学療法耐性を克服するための方法および組成物
AU1197699A (en) 1997-10-23 1999-05-10 Geron Corporation Methods and materials for the growth of primate-derived primordial stem cells
AU758426B2 (en) 1997-10-30 2003-03-20 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Nucleosides for imaging and treatment applications
US6703374B1 (en) * 1997-10-30 2004-03-09 The United States Of America As Represented By The Department Of Health And Human Services Nucleosides for imaging and treatment applications
US6339151B1 (en) * 1998-01-23 2002-01-15 Newbiotics, Inc. Enzyme catalyzed therapeutic agents
GB9821121D0 (en) 1998-09-29 1998-11-25 James Robinson Ltd Grey colouring photochromic fused pyrans
DE69942128D1 (de) 1998-12-11 2010-04-22 Coulter Pharm Inc Prodrugs und verfahren zu deren herstellung
CA2379988C (en) * 1999-07-22 2010-10-19 Newbiotics, Inc. Enzyme catalyzed therapeutic activation
US6683061B1 (en) * 1999-07-22 2004-01-27 Newbiotics, Inc. Enzyme catalyzed therapeutic activation
AU6607200A (en) 1999-07-23 2001-02-13 Westinghouse Electric Company Llc Pulsed gamma neutron activation analysis (pgnaa) method and apparatus for nondestructive assay of containerized contaminants
US6294546B1 (en) * 1999-08-30 2001-09-25 The Broad Of Trustees Of The Leland Stanford Junior University Uses of diterpenoid triepoxides as an anti-proliferative agent
GB0009486D0 (en) 2000-04-17 2000-06-07 Univ Cardiff Chemical compounds
GB0011203D0 (en) 2000-05-09 2000-06-28 Univ Cardiff Chemical compounds
AU2002236455A1 (en) * 2000-11-16 2002-05-27 Newbiotics, Inc. Synergistic ecta compositions
AU2002241911B9 (en) * 2001-01-19 2007-01-25 Celmed Oncology (Usa), Inc. Methods to treat autoimmune and inflammatory conditions

Also Published As

Publication number Publication date
WO1999037753A1 (en) 1999-07-29
EP1167972A2 (de) 2002-01-02
EP1045897A4 (de) 2000-10-25
HK1039520A1 (zh) 2002-04-26
ES2172303T3 (es) 2002-09-16
HK1030624A1 (en) 2001-05-11
US20010034440A1 (en) 2001-10-25
US6245750B1 (en) 2001-06-12
BR9907736A (pt) 2000-10-17
AU2464699A (en) 1999-08-09
PT1045897E (pt) 2002-07-31
EP1167972A3 (de) 2006-05-24
CA2317505A1 (en) 1999-07-29
ATE212661T1 (de) 2002-02-15
EP1045897A1 (de) 2000-10-25
JP3265304B2 (ja) 2002-03-11
DE69900841T2 (de) 2002-10-02
TWI244924B (en) 2005-12-11
EP1167972B1 (de) 2017-03-08
JP2002500880A (ja) 2002-01-15
IL137164A0 (en) 2001-07-24
US6339151B1 (en) 2002-01-15
AU753155B2 (en) 2002-10-10
US7601703B2 (en) 2009-10-13
JP2001220397A (ja) 2001-08-14
CA2317505C (en) 2011-01-04
CN1291228A (zh) 2001-04-11
DK1045897T3 (da) 2002-05-13
CN1192102C (zh) 2005-03-09
EP1045897B1 (de) 2002-01-30

Similar Documents

Publication Publication Date Title
DE69900841T2 (de) Durch enzymkatalyse erhaltene therapeutische substanzen.
EP1004022A4 (de) Methoden und zusammensetzungen zum überwinden der resistenz gegen bio- und chemotherapie
WO2001072962A3 (en) Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
NO993943D0 (no) Kombinert tumorsuppressorgenterapi og kjemoterapi ved behandling av neoplasmer
DE69737684D1 (de) Präzise wirksamkeitsbestimmungsmethode für wirkstoffe einschliesslich chemotherapeutika
EA199700361A1 (ru) Ингибиторы ферментативной активности ротамазы, являющиеся малыми молекулами
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
DK1303757T3 (da) Ionkanal-assayfremgangsmåder
BR0115715A (pt) Análise de expressão de ácidos nucleìcos e polipeptìdeos úteis na diagnose e tratamento de câncer da próstata
ATE512146T1 (de) Phenylharnstoffderivate als hemmstoffe von tyrosinkinasen zur behandlung von tumorerkrankungen
WO2005083086A3 (en) Epha4 as therapeutic target of prc and pdaca
Lane et al. Comparative Cytochrome P450 Proteomics in the Livers of Immunodeficient Mice Using 18O Stable Isotope Labeling* S
WO2002090925A3 (en) Polypeptides and nucleic acids associated with cancer
WO2004005530A3 (en) Compositions and methods for treatment and detection of multiple cancers
BR0113099A (pt) Gene e proteìna relacionados com esquizofrenia
DE60034880D1 (de) Ceramidasegen
WO2006128084A3 (en) Trps1-mediated modulation of hair growth
BR0115728A (pt) Análise da expressão de ácidos nucléicos kiaa e polipeptìdeos úteis no diagnóstico e tratamento de cáncer de próstata
DK0458594T3 (da) Håranalyse
EP1240922A3 (de) Verfahren und Zusammensetzungen zu Überwinden des Widerstands gegen biologische oder chemische Therapie
WO2002044417A3 (en) Expression analysis of inhibitor of differentiation nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
WO2005114216A3 (en) Stamp2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
WO2001006226A3 (de) Verfahren zur bestimmung der proliferationsaktivität von zellen
WO2004092198A3 (en) Compositions and methods for the modifying hypoxia induced gene regulation
PT1080192E (pt) Oligonucleotidos antisentido para o tratamento de celulas proliferativas

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: CELMED ONCOLOGY (USA), INC., SAINT-LAURENT, QUEBEC